Cumberland Pharmaceuticals (NASDAQ:CPIX) Announces Quarterly Earnings Results

Cumberland Pharmaceuticals (NASDAQ:CPIX) posted its earnings results on Tuesday. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, Zacks reports. Cumberland Pharmaceuticals had a negative return on equity of 9.50% and a negative net margin of 29.54%.

Cumberland Pharmaceuticals Price Performance

NASDAQ CPIX opened at $6.05 on Wednesday. Cumberland Pharmaceuticals has a 52 week low of $1.04 and a 52 week high of $7.19. The company has a current ratio of 1.13, a quick ratio of 0.99 and a debt-to-equity ratio of 0.41. The stock has a market cap of $84.95 million, a price-to-earnings ratio of -7.86 and a beta of 0.12. The company has a 50-day moving average price of $3.52 and a two-hundred day moving average price of $2.13.

Analyst Upgrades and Downgrades

Separately, StockNews.com started coverage on shares of Cumberland Pharmaceuticals in a research report on Friday, February 14th. They issued a “hold” rating for the company.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.